April 2022 - A major study elucidating the mechanism of action of the IBD-asset has been completed: Alma's treatment facilitates mucosal healing without immune suppression
March 2022 - WO 2022/070052 A1, a new PCT covering the effect of our IBD-asset on gut dysbiosis and impaired barrier function, was published online.
February 2022 - Alma attended ECCO 2022, the 17th congress of European Crohn's and Colitis Organisation
March 2021 - Alma Bio Therapeutics presented in the biotech session of the special webinar “Bouncing back from the crisis. How to re-establish partnerships between Israel and the Auvergne Rhône-Alpes…
January 2021 – Alma Bio Therapeutics attended the 4th Antigen Specific Immune Tolerance digital event.
September 2020 - Prof. Francisco Javier Quintana of Brigham and Women’s Hospital Harvard Medical School, a world-renowned expert in immune regulation and tolerance, joins Alma’s scientific advisory board.
July 2020 - Alma Bio Therapeutics was among the recipients of PGE, the French government state guaranteed loan.
March 2020 - Alma Bio Therapeutics participated at Digital BioEurope Spring
March 2020 - Alma Bio Theraeutics presented at the RESI Digital partnering event
Dr Binah Baum, Alma Bio Therapeutics CEO, was at the Health Investor Day in Paris on June 24th-25th, 2019.